Cargando…

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy

BACKGROUND: Siponimod is an effective treatment for patients with secondary progressive multiple sclerosis (SPMS), with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, however there is a need to evaluate its economic value and sust...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortesi, Paolo Angelo, Antonazzo, Ippazio Cosimo, Gasperini, Claudio, Nica, Mihaela, Ritrovato, Daniela, Mantovani, Lorenzo Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903273/ https://www.ncbi.nlm.nih.gov/pubmed/35259168 http://dx.doi.org/10.1371/journal.pone.0264123

Ejemplares similares

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2023)

A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy
por: Zambelli, Alberto, et al.
Publicado: (2023)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Siponimod for multiple sclerosis
Publicado: (2021)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
por: Schur, Nadine, et al.
Publicado: (2021)

Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2021)

The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
por: Perrone, Valentina, et al.
Publicado: (2022)

Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Statins Use in Patients with Cardiovascular Diseases and COVID-19 Outcomes: An Italian Population-Based Cohort Study
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply
por: Ferrara, Pietro, et al.
Publicado: (2022)

Patients with multiple sclerosis: a burden and cost of illness study
por: Battaglia, Mario Alberto, et al.
Publicado: (2022)

Azithromycin use and outcomes in patients with COVID-19: an observational real-world study
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod
por: Senzaki, Kensuke, et al.
Publicado: (2021)

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
por: Sabsabi, Sajida, et al.
Publicado: (2022)

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
por: Abbadessa, Gianmarco, et al.
Publicado: (2022)

Time trends in the incidence of essential tremor: Evidences from UK and France primary care data
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
por: Ponticelli, Domenico, et al.
Publicado: (2021)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis
por: Song, Yumeng, et al.
Publicado: (2019)

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod
por: Starke, Ludger, et al.
Publicado: (2023)

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
por: Gold, Ralf, et al.
Publicado: (2022)

Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres
por: Berardi, Lorenzo, et al.
Publicado: (2019)

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
por: Chaoyang, Chen, et al.
Publicado: (2022)

Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review
por: Li, Qingsheng, et al.
Publicado: (2023)

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
por: Cree, Bruce AC, et al.
Publicado: (2022)

Editorial: Overcoming boundaries in public health: Advances in international and global health
por: Antonazzo, Ippazio C., et al.
Publicado: (2022)

Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod
por: Siddiqui, Gulnaz, et al.
Publicado: (2021)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bf6b9noqpo9md634m618rnahka